| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPDD.243 |
| P8608 | Fatcat ID | release_lhlcajge5rdx3hscrw2gg7b5cy |
| P698 | PubMed publication ID | 27163495 |
| P50 | author | David Millson | Q63378747 |
| P2093 | author name string | Paul Martin | |
| David Lau | |||
| Clive Brealey | |||
| Michael Gillen | |||
| Stuart Oliver | |||
| Dominic Surry | |||
| Philip Leese | |||
| David Sweeny | |||
| P2860 | cites work | Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 |
| Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone | Q46496013 | ||
| Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis | Q48933623 | ||
| Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors | Q79984892 | ||
| Fostamatinib Disodium. | Q33405080 | ||
| Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 | ||
| Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database | Q33529391 | ||
| Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes | Q34184221 | ||
| Epidemiology and genetics of rheumatoid arthritis | Q34731244 | ||
| Cardiovascular co-morbidity in rheumatic diseases | Q36835851 | ||
| New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process | Q37124261 | ||
| Cardiovascular risk in rheumatoid arthritis | Q37459157 | ||
| Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. | Q37794960 | ||
| Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation | Q43108099 | ||
| An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents | Q46066669 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 170-179 | |
| P577 | publication date | 2016-03-23 | |
| P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
| P1476 | title | Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies | |
| P478 | volume | 5 |
Search more.